TO BE PUBLISHED May 2025
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
This conference looks at the future of the UK MedTech sector, including the way forward for innovation, improving market access, and accelerating adoption of new technologies within the NHS.
Delegates will assess what will be needed to coordinate regulation, procurement and investment to streamline the introduction of MedTech into clinical use in ways that produce tangible benefits for patient outcomes. They will explore approaches for supporting innovation and sector development, and more effective integration of new technology and treatments into NHS workflows.
Policy and government strategy
The conference will be an opportunity for key stakeholders and policymakers to discuss progress and next steps in light of policy developments, including the forthcoming Life Sciences Strategy and updates to the Medical Devices Regulations coming in to force in June, alongside proposals for international product recognition and evolving MHRA guidance for AI and software-based devices. Sessions will examine the way forward for improving regulatory clarity, as NHS England’s functions are brought under the DHSC.
Procurement and funding
The evolving approach to procurement will be discussed. Delegates will look at implementation of value-based procurement, the NHS Innovation Ecosystem Programme and priorities for improving collaboration between industry, regulators and healthcare providers. Delegates will consider issues around embedding VBP within NHS structures, in light of concerns that cost remains a dominant factor in purchasing decisions, despite policy commitments to prioritise system-wide value and patient outcomes. Further discussion is expected on development of the proposed passport model, and how procurement practice can better support improved accessibility and earlier diagnosis while ensuring high-quality care and value for money.
Delegates will examine priorities for aligning regulatory, procurement and funding frameworks to enable investment and support scale-up, including the development of an integrated rules-based commissioning model. Attendees will also consider the allocation of funding under the Life Sciences Innovative Manufacturing Fund, and implications of the National Procurement Policy Statement for procurement and commissioning support for SME innovation and market access.
Key enablers and the role of AI
Further sessions will bring out latest thinking on supporting NHS-industry partnerships, improving local decision-making and investment in workforce capability, drawing on priorities identified in the NHS Innovation Ecosystem Programme. Delegates will also discuss opportunities for the adoption of AI in diagnostics and patient care, in the context of the AI Opportunities in Healthcare: Action Plan, and consider what is needed in regulatory and procurement frameworks to support implementation and adoption of digital technologies and progress towards NHS net zero targets.
All delegates will be able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices, and more widely. This includes the full proceedings and additional articles submitted by delegates. As well as key stakeholders, those due to attend include officials from DHSC; MHRA; and The Scottish Government.
